MTOR and cancer: Notably, many samples had co-occurring alterations in two cancer-relevant pathways, including 17.2% and 14.7% of samples with a cell cycle pathway alteration as well as a MAPK or PI3K/AKT/mTOR pathway alteration, respectively.